Cost-effectiveness indicator for colorectal cancer therapy
https://doi.org/10.34215/1609-1175-2020-4-24-28
Abstract
Contemporary data on different therapy schemes for colorectal cancer are presented from the point of view of “costeffectiveness” indicator. There is an information about Federal programs aimed at increasing annual healthcare financing connected with preventing and curing malignancies. The statistics of the annual growth in colon and rectum cancer rates is discussed. An actual problem of increasing number of resource-intensive medicines for oncology treatment is stated. This is the reason to analyze cost-effectiveness.
About the Authors
E. V. Eliseeva
Pacific State Medical University
Russian Federation
Russian Federation
MD, PhD, professor, head of the Department of General and Clinical Pharmacology,
2 Ostryakova Ave., Vladivostok, 690002
Yu. Yu. Petukhova
Pacific State Medical University;
Primorskiy Regional Oncological Dispensary
Russian Federation
Russian Federation
postgraduate student;
MD, deputy chief physician, 59 Russian St., Vladivostok, 690105
A. G. Petukhova
Pacific State Medical University
Russian Federation
Russian Federation
student,
2 Ostryakova Ave., Vladivostok, 690002
References
1. Idiyatullina ET, Pavlov VN. Modern aspects of epidemiology, diagnosis and therapy of colorectal cancer. Medical Bulletin of Bashkortostan. 2017;4:115–21 (In Russ).
2. Klinicheskie recomendacii. Zlokachestvenie novoobrazovinia obodochnoi kishki i rectosigmoidnogo otdela. Moscow: Ministry of Health of the Russian Federation; 2020:57 (In Russ).
3. Fedorov VE, Podelyakin KA. Epidemiological aspects of colorectal cancer (review). Medical Almanac. 2017;4:145–8 (In Russ).
4. Prudnikova YaI, Kruchinina MV, Svetlova IO, Kurilovich SA, Voitsitsky VE, Ryaguzov ME, Khadagaev IB. Colorectal cancer: Risk factors and protection. Experimental and Clinical Gastroenterology. 2017;9:96–105 (In Russ).
5. Shtygasheva OV, Ageeva ES, Guzar YaR. Anamnestic predictors of colorectal cancer. Experimental and Clinical Gastroenterology. 2019;2:50–4 (In Russ).
6. Gataullin IG, Ilinskaya ON, Gataullin BI. Bacterial microflora associated with colorectal cancer. Research and Practical Medicine Journal. 2019;6(1S):97 (In Russ).
7. Akhmaltdinova LL, Avdienko OV, Sirota VB, Zhumalieva VA, Turmukhambetova AA. Biomarkers in the diagnosis of colorectal cancer. Medicine and Ecology. 2018;3:11–6 (In Russ).
8. Jahn B, Sroczynski G, Bundo M, Muhlberger N, Puntscher S, Todorovic J, et al. Effectiveness, benefit harm and cost effectiveness of colorectal cancer screening in Austria. BMC Gastroenterol. 2019;19. doi: 10.1186/s12876-019-1121-y.
9. Khalin KD, Agapov MYu, Zvereva LV. Diagnostic value of preoperative biopsy in differential diagnosis of epithelial colorectal tumors. Pacific Medical Journal. 2018;1:41–3 (In Russ).
10. Stanoevich US, Ashikhmina TV, Kolesnikov PG, Ragimov VA, Kharchenko NV. Evolution of surgical treatment of colorectal cancer. Bulletin of the RNCRR. 2017;3:4–17 (In Russ).
11. Dobrova NV, Gordeeva OO, Chernoglazova EV, Tryakin AA. Chemotherapy in the treatment of localized and metastatic colon cancer: New and not yet forgotten old. Medical Council. 2017;14:67–76 (In Russ).
12. Ivanov VA, Gordeev SS, Baychorov AB, Aliev VA, Kuzmichev DV, Polynsky AV, Rasulov AO. Irinotecan in the treatment of colorectal cancer. Oncological Coloproctology. 2017;1:46–56 (In Russ).
13. Dobrova NV, Borisova EI, Darenskaya AD. Results of using tegafur in combination with irinotecan and oxaliplatin in patients with advanced colorectal cancer. Medical Council. 2018;19:42–9 (In Russ).
14. Fedyanin MYu, Tryakin AA., Rogov VA, Ganicheva LM., Frolov MYu, Tyulyandin SA. Pharmacoeconomical features of the choice of systemic therapy for patients with metastatic colon cancer. Oncological Coloproctology. 2017;2:36–42 (In Russ).
15. Loban VI. Combined treatment of metastatic colorectal cancer. Modern Innovation. 2016;4:36–7 (In Russ).
16. Dobrova NV, Arutyunyan EA, Polushkina IN, Aliev VA. Preliminary results of the use of fluorafur in combination with irinotecan and oxaliplatin in patients with advanced colorectal cancer. Oncological Coloproctology. 2017;4:44–53 (In Russ).
17. Zabelin MV, Kaprin AD, Kostin AA, Ganeeva EV, Varlamova SE. EGFR Inhibitors in the treatment of colorectal cancer. Research and Practical Medicine Journal. 2018;3:77–84 (In Russ).
18. Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018;12:3–20.
19. Mirzaev T. The problem of treatment of colorectal cancer. International Scientific Review. 2017;8:73–5 (In Russ).
20. Osumi H, Shinozaki E, Suenaga M, Matsusaka S, Konishi T. RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy. Int J Cancer. 2018;139:803–11.
21. Vladimirova LYu, Abramova NA, Storozhakova AE. Targeted therapy with anti-EGFR monoclonal antibod ies in the treatment of colorectal cancer. Malignant Tumoursis. 2016;4:87–91 (In Russ).
22. Kit OI, Vladimirova LYu, Abramova NA, Storozhakova AE, Kalabanova EA, Kabanov SN, et al. Application of monoclonal antibody-blockers EGFR in the treatment of metastatic colorectal cancer with or without surgical removal of metastases. Russian Journal of Oncology. 2016;1–2:66–71 (In Russ).
23. Zabelin MV, Gordeev SS, Petrov OL, Kostin AA, Varlamova SE. The role of antiangiogenic drugs in the treatment of patients with metastatic colorectal cancer. Oncological Coloproctology. 2018;1:11–8 (In Russ).
24. Kimura M, Usami E, Iwai M, Go M, Teramachi H, Yoshimura T. Comparison of cost-effectiveness of regorafenib and trifluridine/ tipiracil combination tablet for treating advanced and recurrent colorectal cancer. Mol Clin Oncol. 2016;5:635–40.
25. Bolotina LV., Kaprin AD. The second line of targeted therapy for metastatic colorectal cancer. Choice. Medical Council. 2018;19:22–6 (In Russ).
26. Tryakin AA, Balunov PA. Pharmacoeconomical assessment of the use of targeted therapy and chemotherapy. Medical Council. 2018;19:50–5 (In Russ).
27. Avksentiev NA, Derkach EV, Pyadushkina EA, Ter-Ovanesov MD. Cost of treatment of metastatic colorectal cancer in the second and subsequent lines of therapy using targeted drugs. Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology. 2016;2:38–44 (In Russ).
28. Rivera F., Valladares M., Gea S., Lopez-Martinez N. Cost-effectiveness analysis in the Spanish setting of the peak trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wildtype RAS metastatic colorectal cancer. J Med Econ. 2017;20:574–84.
29. Darenskaya AD, Dobrova NV, Medvedeva BM. Cetuximab in the treatment of metastatic colorectal cancer: Background and clinical observation. Medical Council. 2018;19:32–41 (In Russ).
30. Fedyanin MYu, Tyulyandin SA. Choosing the sequence of combinations of chemotherapy drugs and monoclonal antibodies in the treatment of patients with metastatic colon cancer. Malignant Tumoursis. 2018;2:50–9 (In Russ).
Review
For citations:
Eliseeva E.V., Petukhova Yu.Yu., Petukhova A.G. Cost-effectiveness indicator for colorectal cancer therapy. Pacific Medical Journal. 2020;(4):24-28. (In Russ.) https://doi.org/10.34215/1609-1175-2020-4-24-28
Views:
648
Email this article 